Skip to main content
. 2021 Apr 16;2(6):100171. doi: 10.1016/j.jtocrr.2021.100171

Figure 3.

Figure 3

Maximum percentage change from baseline in the sum of all target tumors (Japanese ITT population). (A) RAM + ERL treatment arm. (B) PL + ERL treatment arm. BOR, best overall response; CR, complete response; ERL, erlotinib; ITT, intent-to-treat; PD, progressive disease; PL, placebo; PR, partial response; RAM, ramucirumab; SD, stable disease.